PT  - JOURNAL ARTICLE
AU  - Thomas, Caitlin
AU  - Raibouaa, Afaf
AU  - Wollenberg, Andreas
AU  - Capron, Jean-Philippe
AU  - Krucien, Nicolas
AU  - Karn, Hayley
AU  - Tervonen, Tommi
TI  - Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment
AID  - 10.1136/bmjopen-2021-058799
DP  - 2022 Aug 01
TA  - BMJ Open
PG  - e058799
VI  - 12
IP  - 8
4099  - http://bmjopen.bmj.com/content/12/8/e058799.short
4100  - http://bmjopen.bmj.com/content/12/8/e058799.full
SO  - BMJ Open2022 Aug 01; 12
AB  - Objectives We aimed to quantify patient preferences for efficacy, safety and convenience features of atopic dermatitis (AD) treatments.Design and setting Online discrete choice experiment survey.Participants Adults in the UK, France and Spain who had used AD treatments during the past 2 years.Primary and secondary outcome measures Preferences for attributes were analysed using a multinomial logit model. Willingness to make trade-offs was expressed as the maximum acceptable decrease (MAD) in the probability of achieving clear/almost clear skin at week 16.Results The survey was completed by 404 patients (44.1±12.0 years; 65% women; 64% moderate/severe eczema). Most patients (68%) had no prior experience of using self-injectable treatments for AD or any other illness. Participants most valued increasing the chance of achieving a meaningful reduction in itch at week 16 from 20% to 50%, followed by reducing the risks of serious infections from 6% to 0% and of eye inflammation from 20% to 0%. Participants were willing to accept a decrease in the possibility of achieving clear/almost clear skin to obtain a treatment that can be paused (MAD=24.1%), requires occasional check-ups (MAD=16.1%) or no check-ups (MAD=20.9%) over frequent check-ups, is administered as a one time per day or two times per day oral pill versus a subcutaneous injection every 2 weeks (MAD=16.6%), has a 2-day over 2-week onset of action (MAD=11.3%), and can be used for flare management (MAD=5.8%).Conclusions Although patients with AD most valued treatment benefits and risks, they were willing to tolerate reduced efficacy to obtain a rapid onset, oral administration, less frequent monitoring and a treatment that can be paused. Understanding patients’ preferences for AD therapies, including new targeted therapies, can aid shared decision-making between clinicians and patients and support health technology assessments.No data are available. The data sets generated and/or analysed during the study are not publicly available, because consent was not sought from participants to allow sharing of data with third parties.